

## **ESCAPE-NEXT**

Title: A multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of Nerinetide in participants with acute ischemic stroke undergoing endovascular thrombectomy excluding thrombolysis (ESCAPE-NEXT trial)

Trial number: NCT04462536

Sponsor: NoNo Inc., Toronto, Canada

Coordinating Investigator: Prof. Dr. M. Hill, University of Calgary, Canada

PI KSA: Prof. Dr. med. L. Remonda

Status: recruiting

Summary: Nerinetide is an eicosapeptide, which inhibits post-synaptic density protein 95 (PSD-95), thus altering signaling that leads to neuronal excitotoxicity. Given the results of a subgroup analysis of the ESCAPE-NA1 study the neuroprotective agent Nerinetide might be able to improve clinical outcome in patients with acute ischemic stroke undergoing endovascular thrombectomy and who did not receive intravenous tissue plasminogen activator (iv tPA). The primary objective of the ESCAPE-NEXT trial is to determine the efficacy of the neuroprotectant Nerinetide in reducing disability in participants with acute ischemic stroke treated with endovascular thrombectomy without prior iv tPA.